NCT04436900 is a NA clinical trial of Panretinal Photocoagulation (PRP) in Diabetes Mellitus, Type 2, sponsored by Baqiyatallah Medical Sciences University.

Who is sponsoring NCT04436900?

NCT04436900 is sponsored by Baqiyatallah Medical Sciences University.

What drugs are being tested in NCT04436900?

Interventions in NCT04436900: Panretinal Photocoagulation (PRP).

What condition does NCT04436900 study?

NCT04436900 studies Diabetes Mellitus, Type 2.

Is NCT04436900 still recruiting?

NCT04436900 is currently completed. Last updated 18 June 2020.

Last reviewed 2020-06-18 · How we verify

NCT04436900

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Macular Structural and Functional Function Following Extensive Retinal Laser Therapy in Patients With Proliferative Diabetic Retinopathy

Completed NA Last updated 18 June 2020

What this trial tests

NA trial testing Panretinal Photocoagulation (PRP) in Diabetes Mellitus, Type 2 in 20 participants. Completed in 10 April 2019.

Timeline

10 April 2018

Primary endpoint
10 February 2019

10 April 2019

Quick facts

Lead sponsor	Baqiyatallah Medical Sciences University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	10 April 2018
Primary completion	10 February 2019
Estimated completion	10 April 2019
Sites	1 location across Iran

Drugs / interventions tested

Panretinal Photocoagulation (PRP)

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Baqiyatallah Medical Sciences University

Who can join

Eligibility, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study is a semi-experimental clinical trial that 20 patients (40 eyes) with PDR underwent PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms. The variables of contrast sensitivity, macula thickness under fovea , BCVA, the width of thyroid under fovea , RNFL thickness in the four areas around the disc, and the quality of life questionnaire of all patients were recorded at the beginning of the study.Retinal and choroid under fovea thickness and RNFL thickness were assessed in four areas, one week and one month after the end of treatment, and all the variables mentioned earlier were evaluated three months after PRP surgery. This study is single group that the outcomes are compared before and after the intervention

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Baqiyatallah Medical Sciences University trials

Trials by the same sponsor.

NCT06369688 — IDEAL SKIIN CARES Bundle to Prevent Pressure Injury · NA · not yet recruiting
NCT04463420 — Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 · NA · unknown
NCT04466280 — Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVI · NA · withdrawn
NCT04460092 — Using 32 - Gauge Needles With Lengths of 5 mm and 8 mm on Pain Post-injection, Leak and Blood Glucose · NA · unknown
NCT04376814 — Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04436900 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baqiyatallah Medical Sciences University
Last refreshed: 18 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04436900.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing